

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 September 2023 (14.09.2023)



(10) International Publication Number
WO 2023/170287 A1

(51) International Patent Classification:
C07K 14/50 (2006.01) A23L 29/00 (2016.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2023/056205

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:
10 March 2023 (10.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2203412.8 11 March 2022 (11.03.2022) GB

(71) Applicant: **MULTUS BIOTECHNOLOGY LIMITED**
[GB/GB]; Translation & Innovation Hub, 84 Wood Lane, London W12 0BZ (GB).

(72) Inventors: **PAN, Kevin**; c/o Multus Biotechnology Limited, Translation & Innovation Hub, 84 Wood Lane, London W12 0BZ (GB). **TAYLOR, George Mackford**; c/o Multus Biotechnology Limited, Translation & Innovation Hub, 84 Wood Lane, London W12 0BZ (GB). **MA, Seong Hyun (Brandon)**; c/o Multus Biotechnology Limited, Translation & Innovation Hub, 84 Wood Lane, London W12 0BZ (GB).

(74) Agent: **CMS CAMERON MCKENNA NABARRO OLSWANG LLP**; Cannon Place, 78 Cannon Street, London EC4N 6AF (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: ENGINEERED FIBROBLAST GROWTH FACTOR VARIANTS

(57) Abstract: The invention relates to improved growth factor polypeptide variants, in particular polypeptides comprising a sequence of any one of SEQ ID NOs: 2-7 or a sequence with at least 80% similarity thereto, wherein the FGF polypeptide exhibits increased bioactivity, solubility and/or stability compared to the wild-type FGF2 polypeptide of SEQ ID NO: 1. The invention further provides nucleic acid sequences encoding an FGF polypeptide of the invention and a method of growing an animal cell comprising cultivating the animal cell in a culture medium comprising an FGF polypeptide of the invention is also provided.

WO 2023/170287 A1